Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: February 11, 2026
Reporting Period: Fourth quarter and fiscal year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K serves as a notification that financial results were announced and refers to an attached press release (Exhibit 99.1) for the full data.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the press release referenced as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 11, 2026) for actual financial figures.
- Verify Q4 and full-year 2025 revenue and net income against prior year guidance.
- Check for any updates to future financial guidance or clinical trial milestones mentioned in the press release.
- Confirm cash position and liquidity status as detailed in the full earnings report.